1 |
NCT01940796 |
Terminated |
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) |
- Graft-vs-Host Disease
- GVHD
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 1 |
- Massachusetts General Hospital
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To define the maximum tolerated dose (MTD) of brentuximab vedotin when given as treatment for refractory chronic GVHD
- To test the overall response rate of Brentuximab Vedotin when given as treatment for refractory chronic GVHD
- To identify the toxicities associated with Brentuximab Vedotin when used as therapy for refractory chronic GVHD
- (and 3 more...)
|
19 |
All |
18 Years and older (Adult, Older Adult) |
NCT01940796 |
13-239 |
|
October 2013 |
December 2016 |
December 2016 |
September 12, 2013 |
July 25, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
2 |
NCT02164006 |
Active, not recruiting |
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients |
|
- Drug: TGR-1202 + brentuximab vedotin
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose acceptable for participants
- Overall Response Rate
|
14 |
All |
18 Years and older (Adult, Older Adult) |
NCT02164006 |
TGR-BV-107 |
|
June 2014 |
September 2018 |
February 2019 |
June 16, 2014 |
September 13, 2018 |
|
- TG Therapeutics Investigational Trial Site
Duarte, California, United States - TG Therapeutics Investigational Trial Site
San Diego, California, United States - TG Therapeutics Investigational Trial Site
Sarasota, Florida, United States - TG Therapeutics Investigational Trial Site
Detroit, Michigan, United States
|
|
3 |
NCT02388490 |
Active, not recruiting |
Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas |
- Relapsed or Refractory EBV-and CD30-positive Lymphomas
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 2 |
- Seoul National University Hospital
- Seoul National University Bundang Hospital
- SMG-SNU Boramae Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the overall response rate (ORR) of brentuximab vedotin in EBV- and CD30-positive lymphomas
- To evaluate the safety profile of brentuximab vedotin using CTCAE version 4.03
- To calculate progression-free survival (PFS) time
- (and 2 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT02388490 |
X25016 |
Bretuximab |
March 25, 2016 |
August 2018 |
September 2018 |
March 17, 2015 |
March 9, 2018 |
|
- Seoul National University Bundang Hospital
Seongnam, Korea, Republic of - Seoul National Unversity Hospital
Seoul, Korea, Republic of - SMG-SNU Boramae Medical Center
Seoul, Korea, Republic of
|
|
4 |
NCT03474133 |
Not yet recruiting |
Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) |
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Continuous complete response (CCR) rate
- Additional therapy-free survival (ATFS)
- Overall survival
- Incidence AE according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 [Safety]
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03474133 |
Basalt001 |
BASALT |
September 1, 2018 |
October 1, 2023 |
December 2, 2023 |
March 22, 2018 |
March 22, 2018 |
|
|
|
5 |
NCT03302728 |
Not yet recruiting |
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma |
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Hodgkin Lymphoma
|
- Drug: Lenalidomide 15mg
- Drug: Brentuximab Vedotin 1.8 mg/Kg
|
Interventional
|
Phase 1 |
- Peter MacCallum Cancer Centre, Australia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of the combination of lenalidomide and brentuximab vedotin
- Safety profile of the combination of lenalidomide and brentuximab vedotin
- Treatment intensity.
- (and 4 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03302728 |
17/34 |
EpiBrentlen |
December 15, 2017 |
May 15, 2021 |
August 15, 2021 |
October 5, 2017 |
October 10, 2017 |
|
- Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
|
|
6 |
NCT02169505 |
Terminated |
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) |
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Graft Failure Incidence with Brentuximab Maintenance Post Allogeneic Stem Cell Transplant
- Response Rate
|
2 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02169505 |
2013-0351 NCI-2014-01593 |
|
May 22, 2015 |
August 14, 2017 |
August 14, 2017 |
June 23, 2014 |
January 16, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
7 |
NCT02567851 |
Completed |
A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity |
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- University of Birmingham
- Leukaemia Lymphoma Research
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete metabolic response rate (CMR) after 4 cycles of brentuximab vedotin defined as Deauville score of 1, 2 or 3 by PET
- Tolerability is defined in terms of absence of toxicities related to BV quantified by the CTCAE v4 criteria and dose intensity.
- Overall objective response rate (ORR), including complete or partial metabolic response (CMR/PMR), after 4 cycles and 16 cycles of treatment with BV according to The Lugano Classification
- (and 9 more...)
|
38 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT02567851 |
RG_11-225 2012-000214-11 |
BREVITY |
February 2014 |
January 14, 2016 |
October 2, 2017 |
October 5, 2015 |
May 10, 2018 |
|
- Queen Elizabeth Hospital
Birmingham, United Kingdom - University Hospital of Wales
Cardiff, United Kingdom - Beatson West of Scotland Cancer Center
Glasgow, United Kingdom - (and 9 more...)
|
|
8 |
NCT03007030 |
Recruiting |
Trial of Adcetris in CD30+ Malignant Mesothelioma |
- Lung Diseases Due to External Agents
- Mesothelioma
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Control Rate (DCR) in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin
- Time to Progression in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03007030 |
2016-0514 NCI-2017-00069 |
|
April 5, 2017 |
April 2022 |
April 2022 |
December 30, 2016 |
December 25, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
9 |
NCT03205891 |
Withdrawn |
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas |
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- Classical Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma
- CD30+ Peripheral T-cell Lymphoma
|
- Drug: Brentuximab Vedotin
- Drug: TAK228
- Device: Glucose Monitor
|
Interventional
|
Phase 1 |
- M.D. Anderson Cancer Center
- Takeda
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of Brentuximab Vedotin Administered with TAK228 in Participants with Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell lymphoma and Other CD30+ Peripheral T-Cell Lymphoma Assessed by Dose Limiting Toxicities
- Maximum Tolerated Dose (MTD) of of Brentuximab Vedotin plus TAK228
- Response of Brentuximab Vedotin Administered with TAK228 in Participants with Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell lymphoma and Other CD30+ Peripheral T-Cell Lymphoma Assessed by Dose Limiting Toxicities
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT03205891 |
2016-0854 |
|
March 2018 |
March 2021 |
March 2021 |
July 2, 2017 |
January 17, 2018 |
|
|
|
10 |
NCT03587844 |
Recruiting |
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients |
- Mycosis Fungoides
- Lymphomatoid Papulosis
- Sezary Syndrome
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Seattle Genetics, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
58 |
All |
18 Years and older (Adult, Older Adult) |
NCT03587844 |
18-147 |
|
July 3, 2018 |
July 2020 |
July 2020 |
July 16, 2018 |
February 15, 2019 |
|
- Stanford University Medical Center
Stanford, California, United States - Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - (and 5 more...)
|
|
11 |
NCT02939014 |
Active, not recruiting |
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) |
- Hodgkin Disease
- Lymphoma, Large-Cell, Anaplastic
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
- Number of Participants with Abnormal Clinical Laboratory Findings
- (and 10 more...)
|
39 |
All |
18 Years and older (Adult, Older Adult) |
NCT02939014 |
C25010 U1111-1184-1838 |
|
November 30, 2016 |
August 2, 2018 |
December 1, 2019 |
October 19, 2016 |
September 20, 2018 |
|
- Beijing, Beijing, China
- Guangzhou, Guangdong, China
- Nanjing, Jiangsu, China
- (and 4 more...)
|
|
12 |
NCT02280785 |
Completed |
Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas |
|
- Drug: Brentuximab vedotin
|
Interventional
|
Phase 2 |
- Samsung Medical Center
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall disease control rate
- Progression-free survival (PFS)
- Toxicity (assessed by analyzing adverse events and the standard clinical laboratory and hematologic findings.)
- Overall survival (OS)
|
33 |
All |
19 Years to 75 Years (Adult, Older Adult) |
NCT02280785 |
SMC 2014-04-059 |
BRAN |
November 2014 |
December 2017 |
September 2018 |
November 3, 2014 |
September 6, 2018 |
|
- National Cancer Center
Goyang-si, Gyeonggi-do, Korea, Republic of - Yonsei Severance Hospital
Seoul, Korea, Republic of - Asan Medical Center
Seoul, Korea, Republic of - Korean Cancer Center Hospital
Seoul, Korea, Republic of
|
|
13 |
NCT02096042 |
Terminated Has Results |
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) |
|
- Drug: Brentuximab Vedotin
- Drug: 5-Azacytidine
|
Interventional
|
Phase 1 Phase 2 |
- M.D. Anderson Cancer Center
- Seattle Genetics, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Brentuximab Vedotin in Combination With 5-Azacytidine
- Overall Response Rate
|
1 |
All |
18 Years and older (Adult, Older Adult) |
NCT02096042 |
2013-0706 NCI-2014-01114 |
|
April 2014 |
August 2016 |
August 2016 |
March 26, 2014 |
September 5, 2017 |
September 5, 2017 |
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
14 |
NCT01851200 |
Completed |
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors |
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- Fondazione Michelangelo
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The number of objective responses (partial and complete responses) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 integrated with response of serum tumor markers.
- Progression-Free Survival
- Overall Survival
- Incidence of adverse events related to the study drug
|
9 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01851200 |
FM-12-GCT01 2012-004508-36 |
|
May 2013 |
August 2017 |
September 2017 |
May 10, 2013 |
February 7, 2018 |
|
- Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, Mi, Italy
|
|
15 |
NCT02227433 |
Active, not recruiting |
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. |
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- Fondazione Italiana Linfomi ONLUS
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Antitumor Efficacy
- Survival, safety and tolerability
- Survival
- (and 2 more...)
|
20 |
All |
60 Years and older (Adult, Older Adult) |
NCT02227433 |
FIL_BVHD01 |
FIL_BVHD01 |
February 4, 2013 |
April 3, 2018 |
April 2019 |
August 28, 2014 |
February 8, 2019 |
|
- Irccs Centro Di Riferimento Oncologico Di Aviano (Pn)
Aviano, Italia, Italy - Policlinico S.Orsola Malpighi
Bologna, Italy - Irccs Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli
Napoli, Italy - (and 2 more...)
|
|
16 |
NCT01671813 |
Withdrawn |
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly |
|
- Drug: brentuximab vedotin
|
Interventional
|
Not Applicable |
- H. Lee Moffitt Cancer Center and Research Institute
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Time to Response (TTR)
- Duration of Response (DOR)
- (and 3 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01671813 |
MCC-17024 SGN 35-IST-006 |
|
March 2013 |
July 2013 |
July 2013 |
August 24, 2012 |
July 25, 2013 |
|
|
|
17 |
NCT02588651 |
Recruiting |
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) |
- T-cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Hepato-splenic T-cell Lymphoma
- (and 4 more...)
|
- Drug: Brentuximab vedotin
|
Interventional
|
Phase 2 |
- Deepa Jagadeesh
- Case Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Complete Response
- Progression Free Survival
- (and 4 more...)
|
31 |
All |
18 Years and older (Adult, Older Adult) |
NCT02588651 |
CASE1415 |
|
June 17, 2016 |
June 2019 |
December 2022 |
October 28, 2015 |
November 5, 2018 |
|
- University of Michigan
Ann Arbor, Michigan, United States - Wayne State University, Karmanos Cancer Institute
Detroit, Michigan, United States - Hackensack University Medical Center
Hackensack, New Jersey, United States - (and 2 more...)
|
|
18 |
NCT02423291 |
Completed Has Results |
A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL |
- Primary Mediastinal Large B Cell Lymphoma
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- Fondazione Italiana Linfomi ONLUS
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Objective Response Rate in Patients With Relapsed or Refractory PMLBCL
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT02423291 |
FIL_SGN01 |
FIL_SGN01 |
October 2013 |
July 2016 |
July 2016 |
April 22, 2015 |
June 26, 2017 |
June 26, 2017 |
- S.C. Ematologia A.O. SS. Antonio e Biagio e C. Arrigo
Alessandria, AL, Italy - Unità funzionale di Ematologia A.O.U. Careggi
Firenze, FI, Italy - Dip. Oncologia, Ematologia e Patologie dell'apparato respiratorio A.O.U. Policlinico di Modena
Modena, MO, Italy - (and 6 more...)
|
|
19 |
NCT01393717 |
Completed Has Results |
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma |
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate Among Patients With Salvage Brentuximab Vedotin (BV)
- Complete Response (CR) Rate Among Patients With Salvage Brentuximab Vedotin (BV)
- Overall Response Rate in Cohort #2
- (and 4 more...)
|
57 |
All |
11 Years and older (Child, Adult, Older Adult) |
NCT01393717 |
11051 NCI-2011-01135 |
|
October 20, 2011 |
February 1, 2017 |
February 1, 2017 |
July 13, 2011 |
April 26, 2018 |
April 26, 2018 |
- City of Hope Medical Center
Duarte, California, United States - Weill Medical College, Cornell University
New York, New York, United States
|
|
20 |
NCT03187210 |
Recruiting |
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas |
|
- Drug: Brentuximab Vedotin
- Drug: BeEAM Regimen
|
Interventional
|
Phase 1 Phase 2 |
- University Hospital Inselspital, Berne
- Mundipharma Medical Company
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Dose finding
- Phase 2: Disease free survival at 12 months
- Phase 1: disease-free survival
- (and 2 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03187210 |
BAL-Trial |
BAL |
September 1, 2018 |
June 2021 |
June 2022 |
June 14, 2017 |
September 10, 2018 |
|
- Department for Medical Oncology University Hospital/Inselspital
Berne, Switzerland
|
|
21 |
NCT01990534 |
Active, not recruiting Has Results |
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma |
|
- Drug: Brentuximab vedotin
|
Interventional
|
Phase 4 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Duration of Response (DOR)
- Progression Free Survival (PFS)
- (and 10 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT01990534 |
C25007 2013-000232-10 U1111-1154-2250 NMRR-13-1246-18099 REec-2014-0619 |
|
March 2014 |
March 2016 |
March 2020 |
November 21, 2013 |
May 5, 2017 |
May 5, 2017 |
- Praha, Prague, Czech Republic
- Brno, Czech Republic
- Heidelberg, Baden Wuerttemberg, Germany
- (and 15 more...)
|
|
22 |
NCT02497131 |
Recruiting |
Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients |
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- Fondazione Italiana Linfomi ONLUS
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall objective response rate (ORR)
- Duration of response
- Complete remission rate (CR)
- (and 3 more...)
|
25 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02497131 |
FIL_PTCL_BV |
|
September 2015 |
December 2019 |
December 2021 |
July 14, 2015 |
December 17, 2018 |
|
- Ematologia "L. & A. Seragnoli" - Policlinico S. Orsola Malpighi
Bologna, Italy - A.O.Spedali civili di Brescia
Brescia, Italy - Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori
Milano, Italy - (and 2 more...)
|
|
23 |
NCT01909934 |
Recruiting |
Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma |
- Anaplastic Large-cell Lymphoma
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 4 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR) as assessed by an independent review facility (IRF) according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma
- Duration of response
- Progression-free survival (PFS)
- (and 2 more...)
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT01909934 |
C25006 2012-004128-39 U1111-1154-9784 REec-2014-0649 13/NI/0072 |
|
October 1, 2013 |
October 30, 2019 |
April 23, 2020 |
July 29, 2013 |
July 13, 2018 |
|
- ZNA Stuivenberg
Antwerpen, Belgium - Cliniques Universitaires Saint-Luc
Bruxelles, Belgium - Universitair Ziekenhuis Gent
Gent, Belgium - (and 37 more...)
|
|
24 |
NCT01596218 |
Completed |
Brentuximab Vedotin for Steroid Refractory GvHD |
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 1 |
- Massachusetts General Hospital
- Seattle Genetics, Inc.
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Define MTD of Brentuximab Vedotin
- Overall Response Rate
- Identification of Toxicities
- (and 4 more...)
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT01596218 |
12-094 |
|
July 2012 |
June 2016 |
December 2016 |
May 10, 2012 |
July 25, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - (and 2 more...)
|
|
25 |
NCT02623920 |
Withdrawn |
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
- Diffuse Large B Cell Lymphoma
- Mediastinal Large B-cell Lymphoma
- Grey Zone Lymphoma
- (and 4 more...)
|
- Drug: Brentuximab
- Drug: Bendamustine
- Drug: Rituximab
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CR rate
- Percentage of patients obtaining a CR + PR using Cheson criteria
- Median time to progression
- (and 6 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02623920 |
1507953455 |
S-BR |
December 16, 2015 |
May 17, 2017 |
May 17, 2017 |
December 8, 2015 |
May 19, 2017 |
|
- Arizona Cancer Center at UMC North
Tucson, Arizona, United States
|
|
26 |
NCT02462538 |
Active, not recruiting |
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL |
- ALK+ Anaplastic Large Cell Lymphoma
|
- Drug: Brentuximab vedotin
- Drug: Imatinib
|
Interventional
|
Phase 1 Phase 2 |
- Arbeitsgemeinschaft medikamentoese Tumortherapie
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of brentuximab vedotin and imatinib regime as measured by type, frequency and severity of adverse events (AEs) and their relationship to study treatment
- Efficacy of brentuximab vedotin and imatinib regime as measured by proportion of patients responding to treatment
- Ability to receive further Treatment as measured by number of patients being able to receive transplantation
- (and 2 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02462538 |
AGMT_ALCL1 |
|
May 2015 |
June 2021 |
June 2021 |
June 4, 2015 |
January 10, 2019 |
|
- Universitätsklinik für Innere Medizin V
Innsbruck, Austria - AKH Linz, Innere Medizin 3, Zentrum f. Haematologie u. med. Onkologie
Linz, Austria - Universitätsklinik der PMU, Universitätsklinik für Innere Medizin III
Salzburg, Austria - Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie
Wien, Austria
|
|
27 |
NCT03222492 |
Recruiting |
Brentuximab Vedotin for Systemic Sclerosis |
- Diffuse Cutaneous Systemic Sclerosis
- Scleroderma
- dcSSc
|
- Biological: Brentuximab Vedotin
- Biological: Placebo
|
Interventional
|
Phase 1 Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Immune Tolerance Network (ITN)
- Seattle Genetics, Inc.
|
NIH / Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of participants who experience at least one Grade 3 or higher adverse event
- Proportion of participants who experience at least one Grade 2 or higher adverse event
- Proportion of participants with Grade 2 or higher peripheral neuropathy
- (and 3 more...)
|
24 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03222492 |
DAIT ITN075AI ITN075AI |
BRAVOS |
September 20, 2017 |
September 2020 |
September 2020 |
July 19, 2017 |
September 25, 2018 |
|
- UCLA Medical Center: Division of Rheumatology
Los Angeles, California, United States - Georgetown University Medical Center: Division of Rheumatology
Washington, District of Columbia, United States - Boston University School of Medicine: Rheumatology Section, Scleroderma Clinical Centers
Boston, Massachusetts, United States - (and 8 more...)
|
|
28 |
NCT01841021 |
Terminated Has Results |
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 |
- Peripheral T-Cell Lymphoma
|
- Drug: Brentuximab vedotin
|
Interventional
|
Not Applicable |
- H. Lee Moffitt Cancer Center and Research Institute
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Time to Response (TTR)
- Duration of Response (DOR)
- (and 4 more...)
|
1 |
All |
18 Years and older (Adult, Older Adult) |
NCT01841021 |
MCC-17343 35-IST-019 |
|
April 2014 |
May 2016 |
June 2016 |
April 26, 2013 |
January 19, 2017 |
January 19, 2017 |
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
29 |
NCT02780011 |
Withdrawn |
Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies |
- CD30-positive Lymphoma
- CD30-positive Solid Tumor
|
- Drug: Brentuximab Vedotin
- Drug: Alsertib
|
Interventional
|
Phase 1 |
- Eric Bernicker, MD
- Millennium Pharmaceuticals, Inc.
- The Methodist Hospital System
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD)
- Dose-limiting toxicities (DLTs)
- Recommended phase 2 dose (RP2D)
- (and 2 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02780011 |
Pro00012815 |
AD3LE |
December 2015 |
September 2018 |
September 2018 |
May 23, 2016 |
July 27, 2018 |
|
- Houston Methodist Cancer Center
Houston, Texas, United States
|
|
30 |
NCT01616680 |
Withdrawn |
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease |
- Graft Versus Host Disease
|
- Drug: brentuximab vedotin
- Other: laboratory biomarker analysis
- Other: pharmacological study
|
Interventional
|
Phase 2 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Partial and complete response rates of steroid-resistant acute skin GVHD following administration of brentuximab vedotin
- Complete and partial response rates of gut and liver acute GVHD after administration of brentuximab vedotin
- Incidence and severity of brentuximab vedotin-related toxicity after allogeneic HCT defined graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 4
|
0 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT01616680 |
2589.00 NCI-2012-00921 |
|
September 2012 |
June 2016 |
|
June 12, 2012 |
June 27, 2013 |
|
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
31 |
NCT02244021 |
Completed |
BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV |
- Relapsed/Refractory Hodgkin's Lymphoma
|
- Drug: BRENTUXIMAB VEDOTIN
|
Interventional
|
Phase 2 |
- Fondazione Italiana Linfomi ONLUS
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete response (CR rate)
- PFS
- Neurotoxicity rate
- Duration of remission (DR)
|
13 |
All |
18 Years and older (Adult, Older Adult) |
NCT02244021 |
FIL_BRidge |
|
December 2014 |
July 2016 |
October 2017 |
September 18, 2014 |
February 9, 2018 |
|
- Istituto di Ematologia "L. & A. Seragnoli" , Policlinico S. Orsola Malpighi
Bologna, Italy - Ematologia, IRCCS AOU San Martino-IST
Genova, Italy - Ematologia Ospedale Vito Fazzi
Lecce, Italy - (and 4 more...)
|
|
32 |
NCT01492088 |
Completed Has Results |
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma |
- Relapsed or Refractory Hodgkin Lymphoma
- Relapsed or Refractory Anaplastic Large-cell Lymphoma
|
- Drug: Brentuximab vedotin
|
Interventional
|
Phase 1 Phase 2 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1)
- Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1)
- Number of Participants With Clinically Significant Vital Signs Values Reported as AEs (Phase 1)
- (and 18 more...)
|
36 |
All |
2 Years to 18 Years (Child, Adult) |
NCT01492088 |
C25002 2011-001240-29 U1111-1158-2613 133300410A0384 NL38209.078.11 |
|
April 16, 2012 |
October 12, 2016 |
April 12, 2018 |
December 14, 2011 |
November 20, 2018 |
May 15, 2017 |
- Aurora, Colorado, United States
- Kansas City, Missouri, United States
- New York, New York, United States
- (and 15 more...)
|
|
33 |
NCT01508312 |
Active, not recruiting |
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma |
|
- Drug: brentuximab vedotin (SGN-35)
- Drug: Brentuximab Vedotin (SGN-35)
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Seattle Genetics, Inc.
- Hôpitaux Universitaires Henri Mondor, France
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- rate of FDG-PET/CT normalization
- overall response rate
- Toxicity
|
46 |
All |
12 Years to 72 Years (Child, Adult, Older Adult) |
NCT01508312 |
11-142 |
|
January 5, 2012 |
September 2019 |
September 2019 |
January 11, 2012 |
August 31, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
34 |
NCT01421667 |
Completed Has Results |
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma |
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
|
- Drug: brentuximab vedotin
- Drug: rituximab
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy
- Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Plus Rituximab
- Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Plus Rituximab
- (and 11 more...)
|
176 |
All |
6 Years and older (Child, Adult, Older Adult) |
NCT01421667 |
SGN35-012 |
|
August 2011 |
June 2015 |
June 2015 |
August 23, 2011 |
November 28, 2016 |
October 13, 2016 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - City of Hope
Duarte, California, United States - PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists
Oxnard, California, United States - (and 31 more...)
|
|
35 |
NCT01700751 |
Active, not recruiting |
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation |
- Leukemia, Acute Myeloid
- Leukemia, Lymphoblastic,Acute
- Myelodysplastic Syndromes
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 1 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of brentuximab vedotin when administered with a GVHD prophylaxis regimen
- Safety and tolerability of brentuximab vedotin when administered with a GVHD prophylaxis regimen
- Rate of acute GVHD
- (and 7 more...)
|
17 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01700751 |
201211047 |
|
February 25, 2013 |
November 11, 2015 |
January 31, 2020 |
October 4, 2012 |
March 14, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
|
36 |
NCT01807598 |
Completed Has Results |
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia |
- Aggressive Systemic Mastocytosis
- Mast Cell Leukemia
- Systemic Mastocytosis
|
- Drug: Brentuximab vedotin
|
Interventional
|
Phase 2 |
- Jason Robert Gotlib
- Seattle Genetics, Inc.
- Stanford University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement)
- Brentuximab Vedotin Toxicity
- Percent Change of CD30 Expression on Neoplastic Mast Cells
- (and 5 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT01807598 |
IRB-25727 NCI-2013-00537 107011 HEMMPD0016 |
|
September 2013 |
September 2017 |
September 2017 |
March 8, 2013 |
January 29, 2019 |
January 29, 2019 |
- Stanford University, School of Medicine
Stanford, California, United States - MD Anderson Cancer Center
Houston, Texas, United States
|
|
37 |
NCT02533570 |
Terminated Has Results |
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus |
- Systemic Lupus Erythematosus
|
- Drug: Brentuximab vedotin
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number and Percentage of Subjects Having an Adverse Event (AE)
- Proportion of Subjects Achieving an SRI Response at Day 85
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02533570 |
SGN35-022 |
|
July 2015 |
June 5, 2017 |
June 5, 2017 |
August 27, 2015 |
June 11, 2018 |
June 11, 2018 |
- University of Alabama at Birmingham - (UAB)
Birmingham, Alabama, United States - TriWest Research Associates, LLC
El Cajon, California, United States - Advanced Medical Research, LLC
La Palma, California, United States - (and 14 more...)
|
|
38 |
NCT02429375 |
Active, not recruiting |
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma |
|
- Drug: Mocetinostat Plus Brentuximab Vedotin
|
Interventional
|
Phase 1 Phase 2 |
- Memorial Sloan Kettering Cancer Center
- MethylGene Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- maximum tolerated dose (MTD)
- overall response rate (ORR)
|
7 |
All |
18 Years and older (Adult, Older Adult) |
NCT02429375 |
14-232 |
|
April 2015 |
April 2019 |
April 2019 |
April 29, 2015 |
April 18, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
39 |
NCT01396070 |
Completed Has Results |
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level |
- Non-Hodgkin Lymphoma (NHL)
- Cutaneous Lymphoma
- Cutaneous T-cell Lymphoma (CTCL)
- (and 2 more...)
|
- Drug: Brentuximab vedotin
|
Interventional
|
Phase 2 |
- Youn Kim
- Seattle Genetics, Inc.
- Stanford University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Overall Stable Disease Rate
- Overall Partial Response Rate
- Overall Non-Evaluable Response
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT01396070 |
IRB-21324 LYMNHL0089 SU-06212011-7946 |
|
May 2011 |
April 2015 |
May 2016 |
July 18, 2011 |
April 5, 2017 |
April 5, 2017 |
- Stanford University School of Medicine
Stanford, California, United States
|
|
40 |
NCT02581631 |
Recruiting |
An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas |
|
- Biological: Nivolumab
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 1 Phase 2 |
- Bristol-Myers Squibb
- Seattle Genetics, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of combination of nivolumab and brentuximab vedotin based on incidence of deaths, adverse events (AE), serious adverse events (SAE), AE leading to discontinuation, AE leading to dose delay, drug-related adverse events
- Tolerability of combination of nivolumab and brentuximab vedotin based on incidence of deaths, AE, SAE, adverse events leading to discontinuation, adverse events leading to dose delay, drug-related adverse events
- Overall Response Rate (ORR)
- (and 5 more...)
|
146 |
All |
15 Years and older (Child, Adult, Older Adult) |
NCT02581631 |
CA209-436 2015-003286-28 |
CheckMate 436 |
December 18, 2015 |
June 9, 2019 |
February 13, 2020 |
October 21, 2015 |
September 25, 2018 |
|
- University of Alabama At Birmingham
Birmingham, Alabama, United States - University Of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States - Moffitt Cancer Center
Tampa, Florida, United States - (and 25 more...)
|
|
41 |
NCT02988843 |
Suspended |
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors |
|
- Drug: Brentuximab Vedotin
- Drug: Bevacizumab
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease response rate as defined by the RECIST 1.1 criteria, integrated with tumor marker response.
- Progression free survival
- Overall survival
- Safety/ toxicity of brentuximab vedotin, measured by incidence of AEs/SAEs
|
21 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02988843 |
2015LS190 |
|
March 29, 2017 |
February 2021 |
February 2021 |
December 9, 2016 |
September 26, 2018 |
|
- University of Minnesota
Minneapolis, Minnesota, United States
|
|
42 |
NCT01578499 |
Completed Has Results |
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) |
- Primary Cutaneous Anaplastic Large Cell Lymphoma
- Mycosis Fungoides
- Cutaneous T-Cell Lymphoma
|
- Drug: Brentuximab Vedotin
- Drug: Methotrexate
- Drug: Bexarotene
|
Interventional
|
Phase 3 |
- Millennium Pharmaceuticals, Inc.
- Seattle Genetics, Inc.
- Takeda
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)
- Percentage of Participants Achieving a CR
- Progression-Free Survival (PFS)
- (and 12 more...)
|
131 |
All |
18 Years and older (Adult, Older Adult) |
NCT01578499 |
C25001 2010-024215-14 |
|
June 11, 2012 |
May 31, 2016 |
July 6, 2018 |
April 17, 2012 |
August 21, 2018 |
March 16, 2018 |
- Los Angeles, California, United States
- Palo Alto, California, United States
- Chicago, Illinois, United States
- (and 38 more...)
|
|
43 |
NCT01534078 |
Completed Has Results |
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma |
|
- Drug: Brentuximab Vedotin
- Drug: Adriamycin, vinblastine, and dacarbazine
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate
- Overall Response Rate After One Cycle of Brentuximab
- Overall Response Rate
- Grade III or IV Adverse Events
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT01534078 |
11-462 |
|
March 2012 |
January 2015 |
January 2018 |
February 16, 2012 |
February 20, 2018 |
August 30, 2017 |
- Moffitt Cancer Center
Tampa, Florida, United States - Massachusetts General Hosptial
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
|
44 |
NCT02822586 |
Recruiting |
TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome |
- Mycosis Fungoides
- Sézary Syndrome
|
- Radiation: TSEB Therapy
- Drug: Brentuximab vedotin
|
Interventional
|
Phase 1 |
- Virginia Commonwealth University
- Seattle Genetics, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cutaneous toxicity of combining TSEB and brentuximab vedotin in patients with MF or SS (Cohorts A and B).
- Number of patients who achieved Complete Response (CR) and Partial Response(PR)
- Duration of complete skin response (Cohorts A and B)
- (and 6 more...)
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT02822586 |
MCC-15-10917 IST2015100830 NCI-2016-01509 |
|
December 19, 2016 |
April 1, 2023 |
October 31, 2024 |
July 4, 2016 |
June 27, 2018 |
|
- Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States
|
|
45 |
NCT02499627 |
Recruiting |
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting |
|
- Drug: Brentuximab Vedotin
- Drug: Bendamustine
|
Interventional
|
Phase 2 |
- Fondazione Italiana Linfomi ONLUS
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall objective response rate (ORR).
- Duration of the response (DOR)
- Complete remission (CR) rate
- (and 3 more...)
|
65 |
All |
18 Years to 60 Years (Adult) |
NCT02499627 |
FIL-BBV |
FIL-BBV |
October 2015 |
October 2021 |
October 2021 |
July 16, 2015 |
December 14, 2018 |
|
- A.O S.Orsola-Malpighi
Bologna, BO, Italy - Spedali Civili
Brescia, BS, Italy - Fondazione IRCCS Milano INT
Milano, MI, Italy - (and 4 more...)
|
|
46 |
NCT01805037 |
Unknown † |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
- Adult Grade III Lymphomatoid Granulomatosis
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- (and 114 more...)
|
- Drug: brentuximab vedotin
- Biological: rituximab
- Other: laboratory biomarker analysis
|
Interventional
|
Phase 1 Phase 2 |
- Northwestern University
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- For Phase I: Determine the Dose Limiting Toxicity (DLT) of brentuximab vedotin and rituximab in combination
- Phase I: Determine the Maximum Tolerated Dose (MTD) of brentuximab vedotin and rituximab in combination
- For Phase II: Efficacy of study treatment will be measured by anti-tumor activity as detected from imaging scans
- (and 6 more...)
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT01805037 |
NU 12H09 NCI-2012-03090 STU00072695 |
|
March 2013 |
January 2016 |
|
March 5, 2013 |
April 30, 2015 |
|
- Northwestern University
Chicago, Illinois, United States - University of Chicago
Chicago, Illinois, United States - Tufts University School of Medicine
Boston, Massachusetts, United States
|
|
47 |
NCT02979522 |
Recruiting |
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma |
|
- Drug: Brentuximab vedotin
- Drug: Doxorubicin
- Drug: Vinblastine
- Drug: Dacarbazine
|
Interventional
|
Phase 1 Phase 2 |
- Millennium Pharmaceuticals, Inc.
- Takeda
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Determination of the Recommended Dose of Brentuximab Vedotin in Combination With doxorubicin, vinblastine, and dacarbazine in a Pediatric Population
- Phase 1: Percentage of Participants who Experience Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 days After Administration of the Last Dose of Protocol Therapy
- Phase 1: Percentage of Participants who Experience Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 days After Administration of the Last Dose of Protocol Therapy
- (and 38 more...)
|
55 |
All |
5 Years to 17 Years (Child) |
NCT02979522 |
C25004 2015-004112-38 U1111-1171-0984 |
|
September 7, 2017 |
June 30, 2020 |
October 29, 2021 |
December 1, 2016 |
October 26, 2018 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Children's Hospital Colorado
Aurora, Colorado, United States - Washington University School of Medicine
Saint Louis, Missouri, United States - (and 22 more...)
|
|
48 |
NCT01780662 |
Active, not recruiting |
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma |
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Childhood Hodgkin Lymphoma
- Refractory Childhood Hodgkin Lymphoma
|
- Drug: Brentuximab Vedotin
- Drug: Gemcitabine Hydrochloride
|
Interventional
|
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of brentuximab vedotin in combination with gemcitabine hydrochloride defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity (DLT) as assessed by National Cancer Institute (NCI) CTCAE v 4.0 (Part A)
- Adverse events graded according to NCI CTCAE v4.0 (Part A)
- Complete response (CR) rate
- (and 6 more...)
|
72 |
All |
13 Months to 30 Years (Child, Adult) |
NCT01780662 |
NCI-2013-00107 COG-AHOD1221 AHOD1221 U10CA180886 UM1CA097452 |
|
January 31, 2013 |
September 30, 2017 |
|
January 31, 2013 |
June 26, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Kaiser Permanente Downey Medical Center
Downey, California, United States - (and 113 more...)
|
|
49 |
NCT01657331 |
Active, not recruiting |
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) |
- Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma
|
- Drug: Brentuximab Vedotin
- Drug: Bendamustine
- Drug: Neulasta
|
Interventional
|
Phase 1 Phase 2 |
- Owen A. O'Connor
- Columbia University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of brentuximab vedotin and bendamustine (phase 1)
- Dose limiting toxicities (DLT) of brentuximab vedotin and bendamustine (phase 1)
- Overall Response Rate for the combination of brentuximab vedotin and bendamustine (phase 2)
- (and 3 more...)
|
71 |
All |
18 Years and older (Adult, Older Adult) |
NCT01657331 |
AAAJ5050 |
SGN+Benda |
July 2012 |
March 2019 |
April 2019 |
August 6, 2012 |
April 9, 2018 |
|
- Columbia University Medical Center
New York, New York, United States - British Columbia Cancer Agency
Vancouver, British Columbia, Canada - Princess Margaret Hospital
Toronto, Ontario, Canada
|
|
50 |
NCT02254239 |
Active, not recruiting |
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
|
- Drug: Brentuximab Vedotin
- Drug: Everolimus
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional
|
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of everolimus in combination with brentuximab vedotin, graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Complete response (CR) rate
- Duration of response
- (and 5 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02254239 |
MC1387 NCI-2014-01804 P30CA015083 |
|
February 4, 2016 |
September 30, 2020 |
September 30, 2020 |
October 1, 2014 |
December 19, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
51 |
NCT01900496 |
Terminated |
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma |
|
- Biological: Brentuximab vedotin
- Biological: Rituximab
|
Interventional
|
Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Failure-free survival
- Safety of combination of brentuximab vedotin and rituximab in relapsed classical Hodgkin's Lymphoma
- Survival
- (and 4 more...)
|
6 |
All |
16 Years to 100 Years (Child, Adult, Older Adult) |
NCT01900496 |
J1354 NA_00080336 |
|
June 2014 |
July 2017 |
July 2017 |
July 16, 2013 |
October 17, 2018 |
|
- The Sidney Kimmel Comprehensive Canceer Center
Baltimore, Maryland, United States
|
|
52 |
NCT01830777 |
Active, not recruiting |
Brentuximab Vedotin + Re-induction Chemotherapy for AML |
- Acute Myelogenous Leukemia
|
- Drug: Brentuximab Vedotin
- Drug: Mitoxantrone
- Drug: Etoposide
- Drug: Cytarabine
|
Interventional
|
Phase 1 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Define Maximum Tolerated Dose of Brentuximab Vedotin + MEC
- Detect and Categorize Incidences of Drug Related Toxicities
- Determine Response Rate
- (and 4 more...)
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT01830777 |
13-040 |
|
May 2013 |
April 2018 |
December 2019 |
April 12, 2013 |
November 14, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
53 |
NCT03496779 |
Recruiting |
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine |
- Refractory Peripheral T-Cell Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
|
- Drug: Brentuximab Vedotin - induction
- Drug: Gemcitabine
- Drug: Brentuximab Vedotin - maintenance
- Procedure: autologous or allogeneic stem cell transplantation
|
Interventional
|
Phase 2 |
- The Lymphoma Academic Research Organisation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Progression-Free Survival (PFS)
- Complete Response Rate (CRR)
- (and 7 more...)
|
70 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03496779 |
TOTAL |
|
April 10, 2018 |
March 2020 |
October 2022 |
April 12, 2018 |
June 15, 2018 |
|
- ZNA Stuivenberg
Antwerpen, Belgium - A. Z. Sint-Jan
Bruges, Belgium - Clinique Universitaire Saint LUC
Brussels, Belgium - (and 37 more...)
|
|
54 |
NCT02572167 |
Active, not recruiting |
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma |
|
- Drug: brentuximab vedotin
- Drug: nivolumab
|
Interventional
|
Phase 1 Phase 2 |
- Seattle Genetics, Inc.
- Bristol-Myers Squibb
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events
- Complete response rate
- Objective response rate
- (and 3 more...)
|
93 |
All |
18 Years and older (Adult, Older Adult) |
NCT02572167 |
SGN35-025 |
|
October 2015 |
March 1, 2018 |
October 2020 |
October 8, 2015 |
March 14, 2018 |
|
- City of Hope National Medical Center
Duarte, California, United States - Stanford Cancer Center
Stanford, California, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - (and 10 more...)
|
|
55 |
NCT03373305 |
Not yet recruiting |
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas |
- CD30-Positive Neoplastic Cells Present
- Folliculotropic Mycosis Fungoides
- Recurrent Mycosis Fungoides
- (and 4 more...)
|
- Drug: Brentuximab Vedotin
- Drug: Lenalidomide
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 1 |
- City of Hope Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose limiting toxicity (DLT) assessed per CTCAE v4.0
- Rate of objective global response defined as proportion of patients achieving complete response (CR)/partial response (PR) that lasts at least 4 months
- Complete response defined as proportion of patients achieving CR according to Olsen criteria
- (and 3 more...)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT03373305 |
17347 NCI-2017-02163 |
|
June 2019 |
December 2020 |
December 2020 |
December 14, 2017 |
January 29, 2019 |
|
- City of Hope Medical Center
Duarte, California, United States
|
|
56 |
NCT01771107 |
Recruiting |
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma |
- AIDS-Related Hodgkin Lymphoma
- Ann Arbor Stage II Hodgkin Lymphoma
- Ann Arbor Stage IIA Hodgkin Lymphoma
- (and 9 more...)
|
- Drug: Brentuximab Vedotin
- Drug: Dacarbazine
- Drug: Doxorubicin Hydrochloride
- (and 3 more...)
|
Interventional
|
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximal tolerated dose of brentuximab vedotin when combined with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) chemotherapy regimen, defined as the dose level at which =< 1 of 6 subjects experience dose limiting toxicity (Phase I)
- Progression-free survival for patients using brentuximab vedotin plus AVD regimen with HIV-associated advanced stage Hodgkin lymphoma (Phase II)
- Incidence of adverse events of AVD and brentuximab vedotin with highly active antiretroviral therapy (HAART)
- (and 12 more...)
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT01771107 |
NCI-2013-00046 085 2014-003678-18 AMC-085 UM1CA121947 |
|
March 7, 2013 |
December 12, 2019 |
December 12, 2019 |
January 18, 2013 |
February 6, 2019 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - UCLA Center for Clinical AIDS Research and Education
Los Angeles, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 24 more...)
|
|
57 |
NCT03409432 |
Recruiting |
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma |
- Lymphomatoid Papulosis
- Primary Cutaneous Anaplastic Large Cell Lymphoma
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- (and 6 more...)
|
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- Drug: Lenalidomide
|
Interventional
|
Phase 2 |
- Basem William, MD
- National Cancer Institute (NCI)
- Ohio State University Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Incidence of adverse events according to National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0
- Overall survival (OS)
- Progression free survival (PFS)
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT03409432 |
OSU-17204 NCI-2017-02221 P30CA016058 |
|
March 16, 2018 |
April 30, 2020 |
April 30, 2020 |
January 24, 2018 |
March 20, 2018 |
|
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
|
58 |
NCT02729961 |
Recruiting |
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma |
- Anaplastic Large Cell Lymphoma, ALK-Positive
- CD30-Positive Neoplastic Cells Present
- Systemic Anaplastic Large Cell Lymphoma
|
- Drug: Brentuximab Vedotin
- Drug: Ceritinib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional
|
Phase 1 Phase 2 |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete remission rate defined as the proportion of patients with CR according to the revised Response Criteria for Malignant Lymphoma
- Maximum tolerated dose (MTD) of ceritinib and brentuximab vedotin based on incidence of dose limiting toxicity (DLT) assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
- Objective response rate defined as the proportion of patients with complete response (CR) or partial response (PR) according to the revised Response Criteria for Malignant Lymphoma
- (and 4 more...)
|
30 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT02729961 |
9522 NCI-2016-00396 P30CA015704 |
|
January 3, 2018 |
July 1, 2023 |
July 1, 2023 |
April 6, 2016 |
December 24, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
59 |
NCT01874054 |
Completed Has Results |
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma |
|
- Drug: brentuximab vedotin
- Drug: bendamustine
|
Interventional
|
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Remission Rate
- Incidence of Adverse Events (AEs)
- Incidence of Dose-limiting Toxicities
- (and 3 more...)
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT01874054 |
SGN35-016 |
|
June 2013 |
December 2015 |
February 20, 2018 |
June 10, 2013 |
February 12, 2019 |
April 6, 2017 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Pacific Hematology Oncology Associates
San Francisco, California, United States - Stanford Cancer Center
Stanford, California, United States - (and 10 more...)
|
|
60 |
NCT01461538 |
Completed Has Results |
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies |
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Anemia, Refractory, With Excess of Blasts
- Solid Tumors
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR) by Investigator
- Complete Remission (CR) Rate by Investigator
- Duration of Objective Response by Kaplan-Meier Analysis
- (and 9 more...)
|
84 |
All |
6 Years and older (Child, Adult, Older Adult) |
NCT01461538 |
SGN35-013 |
|
October 2011 |
December 2014 |
December 2014 |
October 28, 2011 |
March 4, 2016 |
March 4, 2016 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - City of Hope
Duarte, California, United States - PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists
Oxnard, California, United States - (and 26 more...)
|
|
61 |
NCT02616965 |
Recruiting |
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma |
- Cutaneous T-cell Lymphoma (CTCL)
|
- Drug: Romidepsin
- Drug: Brentuximab vedotin
|
Interventional
|
Phase 1 |
- Fox Chase Cancer Center
- Seattle Genetics, Inc.
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD)
- Dose-limiting toxicities (DLTs)
- overall safety and tolerability of the combination of brentuximab vedotin & romidepsin assessed by adverse events.
- (and 3 more...)
|
27 |
All |
18 Years and older (Adult, Older Adult) |
NCT02616965 |
HM-085 |
|
February 22, 2017 |
December 2019 |
July 2021 |
November 30, 2015 |
February 23, 2018 |
|
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
|
|
62 |
NCT02689219 |
Recruiting |
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors |
- Germ Cell Tumors
- Testis Cancer
- Testicular Cancer
- (and 2 more...)
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- Costantine Albany
- Indiana University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response (proportion of patients who achieve either a partial or complete response)
- Progression free survival
- Toxicity
|
58 |
All |
18 Years and older (Adult, Older Adult) |
NCT02689219 |
IUSCC-0568 |
|
March 9, 2016 |
December 31, 2018 |
December 31, 2019 |
February 23, 2016 |
February 19, 2018 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - Indiana University Health Hospital
Indianapolis, Indiana, United States - Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States - (and 2 more...)
|
|
63 |
NCT02227199 |
Recruiting |
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
- Recurrent Adult Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- TNFRSF8 Positive
|
- Drug: Brentuximab Vedotin
- Drug: Carboplatin
- Drug: Etoposide
- (and 2 more...)
|
Interventional
|
Phase 1 Phase 2 |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of brentuximab vedotin that can be combined with ifosfamide, carboplatin, and etoposide chemotherapy, defined as the dose at which =< 1 of 6 patients experience a dose-limiting toxicity
- Percentage of patients that achieve a complete remission following study treatment
- Overall survival
- Progression-free survival
|
42 |
All |
18 Years and older (Adult, Older Adult) |
NCT02227199 |
9111 NCI-2014-01782 P30CA015704 |
BV-ICE |
October 10, 2014 |
September 15, 2019 |
|
August 28, 2014 |
November 12, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
64 |
NCT03652441 |
Not yet recruiting |
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma |
- Classical Hodgkin Lymphoma
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 1-year Cumulative incidence of relapse (CIR)
- 1- and 2-year Progression-free survival (PFS)
|
21 |
All |
18 Years and older (Adult, Older Adult) |
NCT03652441 |
Uni-Koeln 3263 2018-000873-59 |
|
October 2018 |
December 2021 |
December 2022 |
August 29, 2018 |
September 5, 2018 |
|
- 1st Department of Medicine, Cologne University Hospital
Cologne, Germany
|
|
65 |
NCT03729609 |
Recruiting |
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma" |
- Untreated CD30-Positive Hodgkin's Lymphoma
|
- Drug: Brentuximab vedotin (Genetical Recombination)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants with Grade 3 or Higher Neutropenia and Febrile Neutropenia
- Tumor Response Rate Based on Investigator's Assessment
|
100 |
All |
Child, Adult, Older Adult |
NCT03729609 |
C25018 JapicCTI-184182 |
|
November 1, 2018 |
May 31, 2022 |
May 31, 2022 |
November 2, 2018 |
November 2, 2018 |
|
- Takeda Selected Site
Tokyo, Japan
|
|
66 |
NCT03057795 |
Recruiting |
Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma |
- Classical Hodgkin Lymphoma
- Hematopoietic Cell Transplantation Recipient
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
|
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS
- Cumulative incidence of non-relapse mortality defined as the time from the first dose of study treatment to non-disease related death
- Cumulative incidence of relapse/progression defined as the time from the first dose of study treatment to disease relapse/progression
- (and 3 more...)
|
65 |
All |
18 Years and older (Adult, Older Adult) |
NCT03057795 |
16378 NCI-2017-00222 |
|
May 3, 2017 |
October 2019 |
October 2019 |
February 20, 2017 |
November 6, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States - Mayo Clinic
Rochester, Minnesota, United States - Hackensack University Medical Center
Hackensack, New Jersey, United States - (and 3 more...)
|
|
67 |
NCT02505269 |
Completed |
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma |
|
- Drug: Brentuximab Vedotin
- Drug: Adriamycin
- Drug: Dacarbazine
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate
- Overall Response Rate
- Rate of grade III and IV adverse events
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT02505269 |
15-196 |
|
August 7, 2015 |
June 2018 |
June 2018 |
July 22, 2015 |
June 12, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
68 |
NCT03138499 |
Recruiting |
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, |
|
- Biological: Nivolumab
- Biological: Brentuximab vedotin
|
Interventional
|
Phase 3 |
- Bristol-Myers Squibb
- Seattle Genetics, Inc.
- Ono Pharmaceutical Co. Ltd
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Complete Response Rate (CRR)
- Objective Response Rate (ORR)
- (and 3 more...)
|
340 |
All |
18 Years and older (Adult, Older Adult) |
NCT03138499 |
CA209-812 2017-000847-41 |
CheckMate 812 |
May 16, 2017 |
November 29, 2020 |
July 27, 2023 |
May 3, 2017 |
November 20, 2018 |
|
- Dr. Moh'd Khushman MD, Office of
Mobile, Alabama, United States - University Of Arkansas For Medical Sciences
Little Rock, Arkansas, United States - City of Hope National Medical Center
Duarte, California, United States - (and 66 more...)
|
|
69 |
NCT02298257 |
Active, not recruiting |
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma |
- HIV Infection
- HIV-associated Hodgkin Lymphoma
- Stage III Adult Hodgkin Lymphoma
- Stage IV Adult Hodgkin Lymphoma
|
- Drug: brentuximab vedotin
- Drug: Doxorubicin Hydrochloride
- Drug: Vinblastine
- Drug: Dacarbazine
|
Interventional
|
Phase 2 |
- The Lymphoma Academic Research Organisation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival for patients using brentuximab vedotin plus AVD regimen with HIV-associated advanced stage Hodgkin lymphoma (Phase II)
- Incidence of adverse events of AVD and brentuximab vedotin with HAART
- Partial response rate
- (and 9 more...)
|
9 |
All |
18 Years and older (Adult, Older Adult) |
NCT02298257 |
AMC-085 |
AMC-085 |
June 2015 |
December 2019 |
December 2019 |
November 21, 2014 |
August 22, 2018 |
|
- APHP - Hôpital Antoine Béclère
Clamart, France - CHU de Nice
Nice, France - APHP - Hôpital Saint Antoine
Paris Cedex 12, France - (and 3 more...)
|
|
70 |
NCT02758717 |
Recruiting |
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma |
- Ann Arbor Stage IB Hodgkin Lymphoma
- Ann Arbor Stage II Hodgkin Lymphoma
- Ann Arbor Stage IIA Hodgkin Lymphoma
- (and 8 more...)
|
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- Academic and Community Cancer Research United
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall metabolic response
- Complete metabolic response rate estimated by the total number of complete metabolic responses (CMR) divided by the total number of evaluable patients
- Duration of response
- (and 3 more...)
|
75 |
All |
Child, Adult, Older Adult |
NCT02758717 |
RU051505I NCI-2016-00468 P30CA015083 |
|
May 13, 2016 |
November 13, 2019 |
May 13, 2024 |
May 2, 2016 |
January 14, 2019 |
|
- Stanford Cancer Institute Palo Alto
Palo Alto, California, United States - MedStar Georgetown University Hospital
Washington, District of Columbia, United States - Emory University/Winship Cancer Institute
Atlanta, Georgia, United States - (and 7 more...)
|
|
71 |
NCT02086604 |
Active, not recruiting |
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma |
- Lymphoma, Large B-Cell, Diffuse
|
- Drug: Brentuximab vedotin
- Drug: Lenalidomide
|
Interventional
|
Phase 1 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety as measured by grade and frequency of adverse events
- Maximum Tolerated Dose (MTD) as measured by the number of dose-limiting toxicities in each dose level (cohort)
- Objective response rate as measured by CD30 expression
- (and 3 more...)
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT02086604 |
201404056 |
|
September 18, 2014 |
June 9, 2017 |
November 30, 2019 |
March 13, 2014 |
June 1, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States - Ohio State University, James Cancer Hospital
Columbus, Ohio, United States
|
|
72 |
NCT01620229 |
Withdrawn |
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
- Hematopoietic/Lymphoid Cancer
|
- Drug: brentuximab vedotin
- Other: laboratory biomarker analysis
- Other: pharmacological study
|
Interventional
|
Phase 1 Phase 2 |
- Fred Hutchinson Cancer Research Center
- Seattle Genetics, Inc.
- National Cancer Institute (NCI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of durable hematopoietic engraftment defined as the achievement of > 50% donor CD3+ cell chimerism
- Rates of relapse
- Non-relapse mortality
- (and 5 more...)
|
0 |
All |
12 Years to 75 Years (Child, Adult, Older Adult) |
NCT01620229 |
2560.00 NCI-2012-00924 P30CA015704 P01CA018029 |
|
June 2013 |
April 2014 |
|
June 15, 2012 |
April 21, 2014 |
|
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
73 |
NCT01950364 |
Completed Has Results |
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma |
- Hodgkin Lymphoma
- Anaplastic Large-cell Lymphoma
|
- Drug: brentuximab vedotin
- Drug: Brentuximab vedotin and rifampicin
|
Interventional
|
Phase 1 |
- Millennium Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose
- Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, Predose
- Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, Predose
- (and 44 more...)
|
20 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01950364 |
C25005 2013-000193-29 U1111-1174-1958 |
|
November 2013 |
October 2014 |
June 2015 |
September 25, 2013 |
May 11, 2016 |
February 9, 2016 |
- Brussels, Belgium
- Gent, Belgium
- Vilnius, Lithuania
- (and 3 more...)
|
|
74 |
NCT01902160 |
Completed |
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
- Recurrent Adult Hodgkin Lymphoma
|
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- Drug: Temsirolimus
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of temsirolimus, determined according to incidence of dose limiting toxicity, graded using the National Cancer Institute Common Terminology Criteria for Adverse v4.0
- Changes in cytokine levels
- Overall response rate (sum of partial responses and complete responses) using the criteria developed by the International Harmonization Project for response assessment in lymphoma
|
3 |
All |
18 Years and older (Adult, Older Adult) |
NCT01902160 |
NCI-2013-01273 13-044 9467 P30CA008748 U01CA069856 |
|
September 2013 |
May 2015 |
|
July 18, 2013 |
November 9, 2015 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
75 |
NCT01578967 |
Active, not recruiting Has Results |
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma |
|
- Drug: Brentuximab vedotin
- Drug: ABVD
|
Interventional
|
Not Applicable |
- UNC Lineberger Comprehensive Cancer Center
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Patients With Positron Emission Tomography (PET) Negative Disease
- Number of Participant Who Achieved a Complete Response
- Conversion Rate to Complete Response. Number of Participants Who Had a Partial Response Post ABVD Who Converted to a Complete Response.
- (and 3 more...)
|
41 |
All |
18 Years to 60 Years (Adult) |
NCT01578967 |
LCCC 1115 |
|
April 2012 |
August 10, 2016 |
August 10, 2021 |
April 17, 2012 |
October 3, 2018 |
October 12, 2017 |
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - Mayo Clinic
Rochester, Minnesota, United States - University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States - (and 3 more...)
|
|
76 |
NCT02744612 |
Recruiting |
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
|
- Drug: Brentuximab Vedotin
- Drug: Ibrutinib
|
Interventional
|
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
- Pharmacyclics LLC.
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CR rate; based on the Cheson criteria
- Duration of overall response
- Number of patients with treatment-related adverse events (overall), scored using the CTCAE version 4.03
- (and 3 more...)
|
39 |
All |
15 Years and older (Child, Adult, Older Adult) |
NCT02744612 |
15334 NCI-2016-00176 |
|
June 20, 2016 |
November 2019 |
November 2019 |
April 20, 2016 |
December 27, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States - University of California San Diego
La Jolla, California, United States - Weill Medical College of Cornell University
New York, New York, United States - Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
|
77 |
NCT02139592 |
Completed |
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" |
- Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
|
- Drug: Brentuximab vedotin (recombinant)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Frequency of adverse events
- Antitumor efficacy (best response)
- Overall survival
|
140 |
All |
Child, Adult, Older Adult |
NCT02139592 |
291-011 JapicCTI-142455 |
|
April 17, 2014 |
June 30, 2017 |
June 30, 2017 |
May 15, 2014 |
July 7, 2017 |
|
|
|
78 |
NCT03264131 |
Recruiting |
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma |
- Lymphoma
- Adult T-Cell Leukemia/Lymphoma
- Lymphatic Diseases
|
- Drug: Brentuximab Vedotin
- Drug: CHEP
|
Interventional
|
Phase 2 |
- UNC Lineberger Comprehensive Cancer Center
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of subjects with Complete Response after 4-6 cycles of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP)
- Overall response rate (ORR) associated with 4-6 cycles of BV-CHEP therapy in patients with adult T-Cell leukemia/lymphoma.
- Progression-free survival (PFS) for BV-CHEP in patients with adult T-cell leukemia/lymphoma who received or did not receive BV maintenance.
- (and 3 more...)
|
28 |
All |
18 Years and older (Adult, Older Adult) |
NCT03264131 |
LCCC 1637 |
|
October 15, 2018 |
January 30, 2021 |
January 30, 2026 |
August 28, 2017 |
January 8, 2019 |
|
- Boston Medical Center
Boston, Massachusetts, United States - Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
|
79 |
NCT01703949 |
Recruiting |
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma |
- CD30-Positive Neoplastic Cells Present
- Recurrent Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- (and 2 more...)
|
- Drug: Brentuximab Vedotin
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate as measured by the Cheson 2007 criteria
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT01703949 |
7808 NCI-2012-01696 P30CA015704 |
|
March 20, 2013 |
January 15, 2021 |
|
October 11, 2012 |
May 30, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
80 |
NCT01026233 |
Completed |
Cardiac Safety Study of Brentuximab Vedotin (SGN-35) |
- Disease, Hodgkin
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Non-Hodgkin
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 1 |
- Seattle Genetics, Inc.
- Millennium Pharmaceuticals, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- QTc interval
- ECG parameters
- Blood MMAE levels
- (and 2 more...)
|
52 |
All |
18 Years and older (Adult, Older Adult) |
NCT01026233 |
SGN35-007 |
|
January 2010 |
August 2010 |
August 2011 |
December 4, 2009 |
December 12, 2014 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - City of Hope National Medical Center
Duarte, California, United States - Stanford Cancer Center
Stanford, California, United States - (and 6 more...)
|
|
81 |
NCT03013933 |
Recruiting |
Brentuximab Vedotin, Cyclosporine, and Verapamil in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- CD30-Positive Neoplastic Cells Present
|
- Drug: Brentuximab Vedotin
- Drug: Cyclosporine
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional
|
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity assessed by National Cancer Institute (NCI) CTCAE version 4.03
- Complete response rate assessed by Cheson 2014 criteria
- Duration of complete response
- (and 5 more...)
|
39 |
All |
15 Years and older (Child, Adult, Older Adult) |
NCT03013933 |
16414 NCI-2016-02062 |
|
May 3, 2017 |
March 2019 |
March 2019 |
January 9, 2017 |
January 23, 2019 |
|
- City of Hope Medical Center
Duarte, California, United States
|
|
82 |
NCT03356054 |
Not yet recruiting |
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse |
|
- Combination Product: R-DHAP
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 1 Phase 2 |
- Stichting Hemato-Oncologie voor Volwassenen Nederland
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The rate of patients with serious toxicity during cycle 1-2 of the combination brentuximab vedotin-R-DHAP
- Metabolic CR rate (PET-diagnostic CT) after the third cycle of brentuximab vedotin-R-DHAP salvage therapy
- Rate of CTCAE grade 3/4 non-hematological toxicity, including neurotoxicity after each cycle of brentuximab vedotin-R-DHAP
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT03356054 |
HO136 2016-001211-21 |
HOVON 136 NHL |
December 2017 |
June 2021 |
June 2025 |
November 29, 2017 |
November 29, 2017 |
|
- ZNA
Antwerp, Belgium - AMC
Amsterdam, Netherlands - VUmc
Amsterdam, Netherlands - (and 14 more...)
|
|
83 |
NCT02594163 |
Terminated Has Results |
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma |
- Diffuse Large B-cell Lymphoma Refractory
- Follicular B-cell Non-Hodgkin's Lymphoma
|
- Drug: Brentuximab Vedotin
- Drug: Rituximab
- Drug: Bendamustine
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Progression-free Survival (PFS)
- Complete Remission (CR) Rate
- (and 3 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT02594163 |
SGN35-023 |
|
October 2015 |
September 2017 |
September 2017 |
November 2, 2015 |
October 16, 2018 |
October 16, 2018 |
- City of Hope
Duarte, California, United States - Sansum Clinic - West Pueblo
Santa Barbara, California, United States - Good Samaritan Hospital
Torrance, California, United States - (and 47 more...)
|
|
84 |
NCT02275598 |
Unknown † |
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma |
|
- Drug: Brentuximab vedotin
- Drug: ABVD
|
Interventional
|
Phase 2 |
- University of Modena and Reggio Emilia
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Complete Metabolic Response by FDG-PET
- Overall Response Rate (ORR)
- Progression Free Survival (PFS)
- Number of Participants with Adverse Events
|
12 |
All |
8 Years to 70 Years (Child, Adult, Older Adult) |
NCT02275598 |
BV-ABVD |
|
April 2013 |
November 2013 |
March 2015 |
October 27, 2014 |
October 27, 2014 |
|
- Institute of Hematology and Medical Oncology "L. e A. Seràgnoli" at the University of Bologna
Bologna, Italy - Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia
Modena, Italy - Hematology, Azienda Ospedaliera Arcispedale S.Maria Nuova IRCCS
Reggio Emilia, Italy
|
|
85 |
NCT02684292 |
Active, not recruiting |
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) |
|
- Biological: pembrolizumab
- Biological: brentuximab vedotin
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS)
- Overall Survival (OS)
- Objective Response Rate (ORR)
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02684292 |
3475-204 2015-005053-12 163337 MK-3475-204 |
|
May 23, 2016 |
December 30, 2018 |
July 31, 2020 |
February 17, 2016 |
July 31, 2018 |
|
|
|
86 |
NCT02280993 |
Active, not recruiting |
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients |
- Hodgkin Lymphoma
- Refractory
- Relapse
|
- Drug: DHAP
- Drug: Brentuximab Vedotin
- Other: Autologous Peripheral Blood Stem Cell Transplantation
|
Interventional
|
Phase 1 |
- Marjolein Spiering
- Millennium: The Takeda Oncology Company
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- rate of patient with grade 4 Adverse Events
- (Severe) Adverse Event
|
72 |
All |
18 Years and older (Adult, Older Adult) |
NCT02280993 |
Transplant BRaVE NL40688.018.12 2012-003097-45 |
|
May 2014 |
November 2018 |
May 2020 |
November 3, 2014 |
March 13, 2018 |
|
- Rigshospitalet
Copenhagen, Denmark - Centre Hospitalier Universitaire
Lille, France - Hospices Civils de Lyon
Lyon, France - (and 10 more...)
|
|
87 |
NCT02927769 |
Recruiting |
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment |
|
- Biological: Nivolumab
- Biological: brentuximab vedotin
- Biological: bendamustine
|
Interventional
|
Phase 2 |
- Bristol-Myers Squibb
- Seattle Genetics, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event Free Survival (EFS)
- Complete Metabolic Response (CMR) rate prior to HDCT/ASCT
- Complete Metabolic Response (CMR) rate at any time prior to radiation therapy
- (and 6 more...)
|
80 |
All |
5 Years to 30 Years (Child, Adult) |
NCT02927769 |
CA209-744 2016-002347-41 |
CheckMate 744 |
March 27, 2017 |
March 28, 2021 |
March 27, 2022 |
October 7, 2016 |
January 1, 2019 |
|
- Children'S Hospital Of Alabama
Birmingham, Alabama, United States - Phoenix Children'S Hospital
Phoenix, Arizona, United States - Loma Linda University Cancer Center
Loma Linda, California, United States - (and 99 more...)
|
|
88 |
NCT00866047 |
Completed Has Results |
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma |
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Non-Hodgkin
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 2 |
- Seattle Genetics, Inc.
- Millennium Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate by Independent Review Group
- Complete Remission Rate by Independent Review Group
- Duration of Objective Response by Kaplan-Meier Analysis
- (and 9 more...)
|
58 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT00866047 |
SG035-0004 2008-006035-12 |
|
March 2009 |
August 2010 |
June 2016 |
March 20, 2009 |
March 22, 2017 |
October 26, 2011 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Stanford University Medical Center
Palo Alto, California, United States - Rocky Mountain Cancer Centers
Denver, Colorado, United States - (and 19 more...)
|
|
89 |
NCT03712202 |
Recruiting |
Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma |
- Ann Arbor Stage I Hodgkin Lymphoma
- Ann Arbor Stage I Lymphocyte-Depleted Classic Hodgkin Lymphoma
- Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma
- (and 11 more...)
|
- Drug: Bleomycin
- Drug: Brentuximab Vedotin
- Drug: Dacarbazine
- (and 4 more...)
|
Interventional
|
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 18-month Progression-free survival (PFS) for each arm of therapy
- Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Scores from European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire C30, version 3 (EORTC-C30) for each arm of therapy
- (and 3 more...)
|
264 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT03712202 |
18157 NCI-2018-01592 |
|
November 28, 2018 |
November 2020 |
November 2020 |
October 19, 2018 |
January 15, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States - City of Hope Medical Center
Duarte, California, United States - (and 27 more...)
|
|
90 |
NCT01896999 |
Recruiting |
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
|
- Drug: Brentuximab Vedotin
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of each combination defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity (DLT) (Phase I)
- CR rate (Phase II)
- Complete response (CR) rate, assessed using the Revised Response Criteria for Malignant Lymphoma (Phase I)
- (and 9 more...)
|
189 |
All |
18 Years and older (Adult, Older Adult) |
NCT01896999 |
NCI-2013-01275 S14-00011 E4412 U10CA180820 U24CA196172 |
|
January 24, 2014 |
May 1, 2029 |
|
July 11, 2013 |
February 15, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 346 more...)
|
|
91 |
NCT02191930 |
Recruiting |
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma |
|
- Drug: B-CAP
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
70 |
All |
60 Years to 99 Years (Adult, Older Adult) |
NCT02191930 |
B-CAP |
B-CAP |
September 2015 |
December 2018 |
April 2019 |
July 16, 2014 |
October 29, 2018 |
|
- 1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany
|
|
92 |
NCT02298283 |
Recruiting |
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD |
|
- Drug: brentuximab vedotin
- Drug: Cyclophosphamide
- Drug: Adriamycin
- (and 7 more...)
|
Interventional
|
Phase 2 |
- The Lymphoma Academic Research Organisation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Complete Response rate (CR rate)
- Overall survival
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02298283 |
BRAPP2 |
BRAPP2 |
April 2015 |
August 2020 |
February 2021 |
November 21, 2014 |
March 7, 2018 |
|
- CH Victor Dupouy
Argenteuil, France - Polyclinique Bordeaux Nord
Bordeaux, France - Centre François Baclesse
Caen, France - (and 27 more...)
|
|
93 |
NCT03198689 |
Not yet recruiting |
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis |
- Diffuse Cutaneous Systemic Sclerosis
|
- Drug: Brentuximab Vedotin
|
Interventional
|
Phase 2 |
- Lawson Health Research Institute
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in skin thickness measured by modified Rodnan Skin Score (mRSS)
- Change in mRSS
- CRISS score >20%
- (and 6 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03198689 |
BV201708 |
|
September 1, 2018 |
November 1, 2018 |
June 1, 2019 |
June 26, 2017 |
May 2, 2018 |
|
- Rheumatology Clinic, St. Joseph's Health Care
London, Ontario, Canada
|
|
94 |
NCT03440788 |
Not yet recruiting |
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin |
- Relapsed or Refractory Hodgkin's Lymphoma
|
- Drug: Brentuximab Vedotin
|
Observational
|
|
- Multinational Center for Quality of Life Research, Russia
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in QoL and symptom severity while treatment with BV
- Overall response rate
- Progression-free survival (PFS)
- Adverse events (AEs)/serious AEs
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT03440788 |
IISR-2017-102112 |
|
March 31, 2018 |
May 1, 2020 |
May 1, 2020 |
February 21, 2018 |
March 22, 2018 |
|
|
|
95 |
NCT01994850 |
Active, not recruiting |
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas |
- CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Positive Diffuse Large B-cell Lymphoma or CD30 Positive Grey Zone Lymphoma
|
- Drug: brentuximab vedotin
|
Interventional
|
Phase 1 Phase 2 |
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Primary Purpose: Treatment
|
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT01994850 |
UPCC 17413 |
|
November 2013 |
July 2017 |
|
November 26, 2013 |
July 6, 2017 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
|
96 |
NCT01196208 |
Available |
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 |
- Disease, Hodgkin
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell, Cutaneous
|
- Drug: brentuximab vedotin
|
Expanded Access
|
|
- Seattle Genetics, Inc.
- Millennium Pharmaceuticals, Inc.
|
Industry |
|
|
|
All |
6 Years and older (Child, Adult, Older Adult) |
NCT01196208 |
SGN35-010 2010-020363-21 |
|
|
|
|
September 8, 2010 |
September 17, 2018 |
|
- Stanford Cancer Center
Stanford, California, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - MD Anderson Cancer Center / University of Texas
Houston, Texas, United States - (and 28 more...)
|
|
97 |
NCT01979536 |
Suspended |
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma |
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- (and 2 more...)
|
- Drug: Brentuximab Vedotin
- Drug: Crizotinib
- Drug: Cyclophosphamide
- (and 7 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of grade 3+ non-hematologic adverse events, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Event free survival (EFS)
- Changes on levels of minimal residual disease
|
140 |
All |
up to 21 Years (Child, Adult) |
NCT01979536 |
NCI-2013-02167 s14-01970 COG-ANHL12P1 ANHL12P1 U10CA180886 U10CA098543 |
|
November 8, 2013 |
December 31, 2021 |
December 31, 2021 |
November 8, 2013 |
February 18, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 151 more...)
|
|
98 |
NCT01060904 |
Completed |
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma |
|
- Drug: brentuximab vedotin
- Drug: doxorubicin
- Drug: vinblastine
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Seattle Genetics, Inc.
- Millennium Pharmaceuticals, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events and laboratory abnormalities
- Brentuximab vedotin concentration in blood
- Antitherapeutic antibodies in blood
- Best clinical response
|
51 |
All |
18 Years to 60 Years (Adult) |
NCT01060904 |
SGN35-009 |
|
January 2010 |
September 2012 |
September 2012 |
February 2, 2010 |
December 18, 2014 |
|
- Mayo Clinic
Rochester, Minnesota, United States - UNC Lineberger Comprehensive Cancer Center / University of North Carolina
Chapel Hill, North Carolina, United States - MD Anderson Cancer Center / University of Texas
Houston, Texas, United States - British Columbia Cancer Agency - Vancouver Centre
Vancouver, British Columbia, Canada
|
|
99 |
NCT02686346 |
Active, not recruiting |
Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE |
|
- Drug: Brentuximab Vedotin
- Drug: Etoposide
- Drug: Carboplatine
- Drug: Ifosfamide
|
Interventional
|
Phase 1 Phase 2 |
- The Lymphoma Academic Research Organisation
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I : Maximal Tolerated Dose (MTD) determination
- Phase II = fraction of responding patients according to Lugano classification (metabolic Complete Response)
- Phase I : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
- (and 9 more...)
|
53 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02686346 |
BV-ICE |
BV-ICE |
March 2016 |
October 31, 2018 |
July 2021 |
February 19, 2016 |
January 3, 2019 |
|
- Clinique Universitaire Saint-Luc
Bruxelles, Belgium - CHU Dinant Godinne
Yvoir, Belgium - Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre
Caen, France - (and 16 more...)
|
|
100 |
NCT02734771 |
Recruiting |
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) |
- Diffuse Large B-Cell Lymphoma
|
- Drug: Brentuximab vedotin
- Drug: Rituximab
- Drug: Cyclophosphamide
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Patrick Reagan
- Seattle Genetics, Inc.
- University of Rochester
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent of Subjects Completing Regimen
- Overall Survival
- Progression Free Survival
- (and 2 more...)
|
24 |
All |
75 Years and older (Older Adult) |
NCT02734771 |
ULYM15105 IST-2014-100578 |
BV mini CHP |
June 2016 |
June 2019 |
June 2021 |
April 12, 2016 |
September 14, 2018 |
|
- James P. Wilmot Cancer Institute, University of Rochester Medical Center
Rochester, New York, United States - University of Virginia Cancer Center
Charlottesville, Virginia, United States
|
|